Observational studyBMJ open respiratory research2026
Pulmonary hypertension in Takayasu arteritis with pulmonary artery involvement: risk factors and impact on mortality.
Observational study in BMJ open respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07184814 (Clinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary artery involvement (PAI) in Takayasu arteritis (TAK) can cause pulmonary hypertension (PH). We aimed to compare clinical and imaging features between TAK patients with and without PH, identify factors associated with PH and describe long-term outcomes.
methodsA prospective cohort of 147 TAK patients was studied from 2016 to 2024. Eligibility required fulfilment of established TAK criteria or multidisciplinary confirmation of CT-proven PAI after exclusion of other causes. Baseline demographics, clinical symptoms, laboratory and imaging findings, haemodynamic parameters and treatments were collected. The primary endpoint was all-cause mortality. Logistic regression identified factors associated with PH, and Cox proportional hazards regression evaluated predictors of mortality.
resultsAmong 87 TAK-PAI patients, 40 (46%) had PH. Compared with non-PH patients, those with PH had higher Qanadli scores, longer diagnostic delay (median 20.5 vs 6.0 months, p=0.011), more severe symptoms, worse cardiopulmonary function, and higher N-terminal pro-B-type natriuretic peptide and right ventricular dimension (all p<0.01). During a median follow-up of 32 months, all eight deaths occurred in the PH group, seven without balloon pulmonary angioplasty. Kaplan-Meier survival was significantly worse for PH (p=0.0025). Multivariable analysis identified female sex (OR 4.543; 95% CI 1.103 to 18.717, p=0.036), higher Qanadli score (OR 14.729; 95% CI 2.718 to 79.809, p=0.002), uric acid (OR 1.007; 95% CI 1.002 to 1.013, p=0.010) and diagnostic delay per month (OR 1.036; 95% CI 1.010 to 1.063, p=0.006) as independent risk factors for PH. Worse WHO-functional class predicted mortality (HR 4.832; 95% CI 1.121 to 20.832, p=0.035).
conclusionsPH occurs in nearly half of TAK-PAI patients and is linked to severe symptoms, functional impairment and increased mortality. Higher Qanadli score, hyperuricaemia and delayed diagnosis are independent risk factors. Early recognition and timely intervention may improve outcomes. TRIAL REGISTRATION NUMBER: NCT07184814.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.